Clinical Trials Using Tocilizumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Tocilizumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 27
1 2 Next >

  • A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

    A Phase Ib / II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. In each cohort, eligible patients will be assigned to one of several treatment arms.
    Location: 12 locations

  • A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

    This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of intravenous mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL) and in participants with follicular lymphoma (FL). It will consist of a dose finding portion followed by an expansion phase for second line or later (2L+) participants with relapsed or refractory (R / R) DLBCL and 2L+ R / R FL. In addition, subcutaneous mosunetuzumab in combination with polatuzumab vedotin will be evaluated in participants with at least 2 prior lines of systemic therapy for the treatment of R / R mantle cell lymphoma (MCL).
    Location: 10 locations

  • A Phase Ib / II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

    This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R / R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).
    Location: 9 locations

  • Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R / R MM)

    This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R / R MM).
    Location: 10 locations

  • A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

    CO40939 is a Phase Ib, open-label, multicenter, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of cibisatamab in combination with atezolizumab administered after pretreatment with obinutuzumab in patients with Stage IV microsatellite stable (MSS) metastatic colorectal cancer (mCRC) whose tumors have high carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression and who have progressed on two or more chemotherapy regimens. The study is composed of a safety run-in and an exploratory part.
    Location: 8 locations

  • Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly / Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

    This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease or partial response, or in elderly / unfit participants with previously untreated DLBCL, or subcutaneous mosunetuzumab in combination with polatuzumab vedotin IV in elderly / unfit participants with previously untreated DLBCL.
    Location: 6 locations

  • A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed / Refractory B-Cell Non-Hodgkin's Lymphoma

    This is a Phase I / II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. This entry-to-human study is divided in 3 parts: dose escalation (Parts I and II) and dose expansion (Part III). Single-participant dose-escalation cohorts will be used in Part I, followed by conversion to multiple participant dose-escalation cohorts (Part II), in order to define a tentative maximum tolerated dose (MTD) or optimal biological dose (OBD). The expansion cohorts (Part III) will be initiated when the tentative MTD / OBD is defined, to further evaluate the safety, PK and therapeutic activity of glofitamab.
    Location: 6 locations

  • Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Unresectable Stage IIIb-IV Melanoma

    This phase II trial studies the side effects and how well tocilizumab, ipilimumab, and nivolumab work in treating patients with stage IIIb-IV melanoma that cannot be removed by surgery (unresectable). Tocilizumab is a monoclonal antibody that works by blocking the receptor of the interleukin-6 (IL-6) protein in the body. IL-6 is a protein thought to help cancer cells grow and survive against the body’s defense mechanisms. Tocilizumab blocks the receptor of the IL-6 protein, which prevents the IL-6 protein from functioning. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tocilizumab, ipilimumab, and nivolumab may work better in treating patients with melanoma compared to ipilimumab and nivolumab alone.
    Location: 4 locations

  • A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

    This is a Phase Ib / II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
    Location: 4 locations

  • A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer

    This is a Phase Ib / II, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic or inoperable locally advanced TNBC. The study will be performed in two stages. During Stage 1, two cohorts will be enrolled in parallel in this study: one cohort will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line [1L] PD-L1+ cohort), and one cohort will consist of participants who had disease progression during or following 1L treatment with chemotherapy (e.g., paclitaxel, nab-paclitaxel, carboplatin) and have not received cancer immunotherapy (CIT) (second-line [2L] CIT-naive cohort). In addition, participants in the 2L CIT-naive cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination (Stage 2), provided Stage 2 is open for enrollment.
    Location: 4 locations

  • A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

    This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in patients with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: the first-line (1L) cohort will consist of patients who have not received any systemic therapy for their disease and the second-line (2L) cohort will consist of patients who progressed during or after receiving a platinum-containing regimen and a PD-L1 / PD-1 checkpoint inhibitor treatment. In each cohort, eligible patients will be assigned to one of several treatment arms.
    Location: 4 locations

  • Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

    A Phase Ib / II, open-label, multicenter, randomized, umbrella study in participants with cisplatin-ineligible MIBC and in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population (e.g., with regard to prior anti-cancer treatment or biomarker status). Participants in the mUC Cohort who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen for Stage 2.
    Location: 3 locations

  • Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

    Primary Objective: To evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed / Refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML) Secondary Objectives: - Safety and tolerability assessments - Assessment of infusion reactions (IRs) - Pharmacokinetics (PK) of isatuximab - Minimal residual disease - Overall response rate - Overall survival - Event free survival - Duration of response - Relationship between clinical effects and CD38 receptor density and occupancy
    Location: 2 locations

  • Atezolizumab with or without Tocilizumab or Etrumadenant in Treating Men with Localized Prostate Cancer before Radical Prostatectomy

    This phase II trial studies how well atezolizumab works alone or in combination with tocilizumab or etrumadenant in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tocilizumab is an antibody (a protein similar to those produced by the body's immune system) that binds to a protein called IL-6R. High levels of IL-6 may promote tumor growth. Blocking IL-6R with tocilizumab may reset the immune system to recognize the tumor and help shrink it. Etrumadenant may block the suppression (stopping) of the immune system caused by adenosine (a hormone in your body) and cancer cells. We want to see how effective atezolizumab and tocilizumab or etrumadenant are when used together for people with advanced local prostate cancer.
    Location: 3 locations

  • Atezolizumab with or without Tocilizumab, Tiragolumab, or Other Immune Modulating-Agents in Treating Patients with Head and Neck Squamous Cell Cancer

    This phase II trial studies how well atezolizumab works in treating patients with head and neck squamous cell cancer, and if adding atezolizumab to the standard-of-care treatment (surgical resection followed by radiation or chemoradiation) decreases the occurrence of cancer relapse. Atezolizumab is an antibody (a protein used by the body's immune system to identify and neutralize foreign substances such as bacteria, viruses, and tumor cells) that affects the immune system by blocking the PD-L1 pathway. The PD L1 pathway is involved in decreasing the body’s natural immune response to fight cancer. By blocking the PD-L1 pathway, atezolizumab may help your immune system stop or reverse the growth of tumors. Tocilizumab is an antibody (a protein similar to those produced by the body's immune system) that binds to a protein called IL-6R. High levels of IL-6 may promote tumor growth. Blocking IL-6R with tocilizumab may reset the immune system to recognize the tumor and help shrink it. The body’s immune system has a certain natural ability to withstand tumor growth. Tumors partially resist the immune system and atezolizumab may help your immune system to withstand the growth of tumors. Tiragolumab is an antibody, a type of protein used by your body's immune system to identify and attack foreign objects, such as bacteria, viruses, and tumor cells. The body’s immune system has the ability to recognize and fight harmful infections and cancer. Tumors can partially decrease the immune system from functioning properly using a pathway known as TIGIT. Tiragolumab, which is manufactured in a laboratory, acts by blocking the TIGIT protein which may help boost the immune system and stop or reverse the growth of tumors. Giving atezolizumab in combination with tocilizumab or tiragolumab may have additional immune effects against tumors. The purpose of this study is to investigate the effect of atezolizumab or atezolizumab in combination with tocilizumab or tiragolumab on infiltration of the tumor by T-cells (a type of white blood cell).
    Location: 2 locations

  • Trastuzumab, Pertuzumab, Tocilizumab in Treating Participants with Metastatic or Unresectable HER2 Positive Breast Cancer

    This phase I trial studies the best dose and side effects of trastuzumab, pertuzumab and tocilizumab in treating participants with HER2 positive breast cancer that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies such as trastuzumab, pertuzumab and tocilizumab, may interfere with the ability of tumor cells to grow and spread
    Location: 2 locations

  • A Study of Rituximab or Tocilizumab for Cancer Patients that Develop Immunotherapy-Related Side Effects Requiring Prolonged Steroid Use

    This phase II trial investigates how well either rituximab or tocilizumab work in treating cancer patients who have developed side effects while on immunotherapy that require prolonged use of steroids. Immune-related side effects are caused by activation of the immune system from treatment with immunotherapy. Steroids can cause many side effects with prolonged use including problems with sleep, weight gain, diabetes, muscle loss, high blood pressure, high cholesterol, bone loss, and mood disturbances. Rituximab and tocilizumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. Giving rituximab or tocilizumab may manage immune-related side effects and ultimately help cancer patients get off steroids.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Itacitinib and Tocilizumab for the Treatment of Steroid Refractory Acute Graft versus Host Disease

    This phase I trial studies the side effects and best dose of itacitinib and tocilizumab in treating patients with acute graft versus host disease that does not respond to steroid therapy (steroid refractory). Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tocilizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving itacitinib and tocilizumab may be beneficial in treating patients with steroid refractory acute graft versus host disease.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Modified Immune Cells (CD19 / CD20 CAR-T Cells) in Treating Patients with Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

    This phase I trial studies the side effects and best dose of CD19 / CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's B-cell lymphoma or chronic lymphocytic leukemia that has come back (recurrent) or has not responded to treatment (refractory). In CAR-T cell therapy, a patient's white blood cells (T cells) are changed in the laboratory to produce an engineered receptor that allows the T cell to recognize and respond to CD19 and CD20 proteins. CD19 and CD20 are commonly found on non-Hodgkin’s B-cell lymphoma and chronic lymphocytic leukemia cells. Chemotherapy drugs such as fludarabine phosphate and cyclophosphamide can control cancer cells by killing them, by preventing their growth, or by stopping them from spreading. Combining CD19 / CD20 CAR-T cells and chemotherapy may help treat patients with recurrent or refractory B-cell lymphoma or chronic lymphocytic leukemia.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Tocilizumab in Treating Children and Adolescents with Newly-Diagnosed, Recurrent, or Progressive Adamantinomatous Craniopharyngioma

    This early phase I trial studies how well tocilizumab works in treating children and adolescents with adamantinomatous craniopharyngioma that is newly diagnosed, has come back (recurrent), or is growing, spreading, or getting worse (progressive). Immunotherapy with tocilizumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread.
    Location: Children's Hospital Colorado, Aurora, Colorado

  • A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participants With DLBCL

    This is a phase 1B, multi-center, dose-finding study of glofitamab administered in combination with obinutuzumab (Gazyva; [G]), rituximab (R) and standard doses of CHOP (G / R-CHOP or R-CHOP) in participants with r / r NHL and untreated diffuse large B-cell lymphoma (DLBCL). Evaluating the safety, preliminary activity, pharmacokinetic (PK), and pharmacodynamic effects of this combination will be the main objectives of this study. The study is divided in two parts: - Part I: Dose finding in participants with r / r NHL; test use of G vs R in Cycle 1 - Part II: Dose Expansion. The maximum tolerated dose or optimal biological dose (MTD or OBD) will be further assessed in participants with r / r NHL and those with untreated DLBCL (>60 years of age with an age-adjusted International Prognostic Index (IPI) of 2-3). Particularly, the impact of using glofitamab plus G / R-CHOP (i.e., add-on arm) versus glofitamab plus CHOP (i.e., replacement arm) will be assessed in untreated DLBCL participants.
    Location: 2 locations

  • Autologous IC9-CAR19 T cells in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia

    This phase I trial studies the side effect of autologous inducible caspase 9 chimeric antigen receptor targeting CD19 antigen (iC9-CAR19) T cells in treating patients with acute lymphoblastic leukemia that has come back (recurrent) or does not respond to treatment (refractory). IC9-CAR19 T cells combines antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances and by stopping them from growing. T cells are special infection fighting blood cells that can kill other cells, including cancer cells or cells that are infected.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Alemtuzumab or Tocilizumab in Combination with Etoposide and Dexamethasone in Treating Patients with Hemophagocytic Lymphohistiocytosis

    This phase II trial studies how well alemtuzumab or tocilizumab in combination with etoposide and dexamethasone work in treating patients with hemophagocytic lymphohistiocytosis. Hemophagocytic lymphohistiocytosis is a disorder that causes abnormal over activity of the immune system. Immunosuppressive therapy, using drugs such as alemtuzumab, tocilizumab, etoposide, and dexamethasone, may decrease the body’s immune system activity and prevent the immune system from causing damage to organs.
    Location: M D Anderson Cancer Center, Houston, Texas

  • A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

    This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and / or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and / or subcutaneous (SC) administrations of RO7293583 with or without obinutuzumab pretreatment, in participants with unresectable metastatic TYRP1-positive melanomas who have progressed on standard of care (SOC) treatment, are intolerant to SOC, or are non-amenable to SOC. This study will include an initial single participant dose-escalation part one followed by a multiple participant dose-escalation part two with the possibility of expansion.
    Location: 2 locations

  • A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed / Refractory Diffuse Large B-Cell Lymphoma

    This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R / R DLBCL.
    Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey


1 2 Next >